John Crowley, Amicus chairman and CEO
In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan
Amicus received a healthy heaping of good news last month when analysts threw cold water on Sanofi’s late-onset Pompe disease ERT, after a Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
